[{"id":"2a0f5205-d6a9-4bf7-8102-4679f08adbff","acronym":"","url":"https://clinicaltrials.gov/study/NCT03583125","created_at":"2021-01-18T17:37:37.192Z","updated_at":"2024-07-02T16:36:55.780Z","phase":"Phase 1","brief_title":"Study of EOC317 in Chinese Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT03583125","lead_sponsor":"Taizhou EOC Pharma Co., Ltd.","biomarkers":" FGFR","pipe":"","alterations":" ","tags":["FGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EOC317"],"overall_status":"Unknown status","enrollment":" Enrollment 140","initiation":"Initiation: 05/29/2018","start_date":" 05/29/2018","primary_txt":" Primary completion: 02/29/2020","primary_completion_date":" 02/29/2020","study_txt":" Completion: 11/29/2020","study_completion_date":" 11/29/2020","last_update_posted":"2019-09-11"}]